Valsartan Recall in US – Opportunity Coming To End
Post the recall of Valsartan formulations (generics of Diovan) by various generics in the US, a shortage was created resulting in significant price...
493 Views
EM Strategy: Remain Overweight India
In this report we provide a synopsis of EM markets. We also scour the EM universe for attractive and actionable opportunities, highlighting...
426 Views
Para IV Winners and Losers - July 2018
This month’s Para IV developments suggest that there is likely to be benefit to Par Pharma, Dr. Reddy'S Laboratories (DRRD IN) & Amneal...
291 Views
Para IV Winners and Losers - June 2018
This month’s Para IV developments suggest that there is likely to be benefit to Baxter International Inc (BAX US) on Premix Precedex (4mc/ml), Endo...
336 Views
Para IV Winners & Losers - May 2018
This month’s Para IV developments suggest that there is likely to be benefit to Amneal Pharmaceuticals Inc (AMRX US) on Lialda, BioQ pharma for...
122 Views